MedImmune readies for $250 million facility expansion

By Lisa Kerner

Charlotte, N.C., Sept. 13 - MedImmune, Inc. said it broke ground to expand its biologics manufacturing facility in Frederick, Md.

The $250 million expansion will increase the pharmaceutical company's cell culture production capacity in anticipation of future monoclonal antibodies currently in development.

MedImmune recently received a $170 million, five-year contract from the U.S. Department of Health and Human Services to develop cell culture-based seasonal and pandemic vaccines.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.